Global Hypertrophic Cardiomyopathy
Therapeutics Market 2017-2021
No of Pages – 70
Publishing Date - April 5, 2017
Browse detailed TOC, Tables, Figures, Charts in Global Hypertrophic Cardiomyopathy
Therapeutics Market 2017-2021 at - http://www.360marketupdates.com/10574953
ABSTRACT
About Hypertrophic Cardiomyopathy Therapeutics
HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart.
HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any
age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers
to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized
by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various
organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital
organs.
Technavio’s analysts forecast the global hypertrophic cardiomyopathy therapeutics market to grow
at a CAGR of 1.80% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global hypertrophic
cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents
a detailed picture of the market by way of study, synthesis, and summation of data from multiple
sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been
prepared based on an in-depth market analysis with inputs from industry experts. The report covers
the market landscape and its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Merck
• Pfizer
• Sanofi
Other prominent vendors